Piper Sandler analyst Jason Bednar raised the firm’s price target on Merit Medical to $97 from $95 and keeps an Overweight rating on the shares. The firm notes Merit Medical announced Q1 results that included revenue of $324M/+9.3% cc and EPS of 77c, a solid beat vs. Street’s $316M and 71c, with strength in Peripheral Intervention and a healthy gross margin percentage driving the upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI: